South Korean medical diagnostic company NGeneBio Co. has partnered with MP Group, a large consignment testing agency in Thailand, to launch a precision cancer test service based on next-generation sequencing (NGS).
On Jan. 30, NGenBio presented the need for NGS precision diagnosis and introduced its products at an event hosted by MP Group. The event was attended by more than 100 major medical officials in Thailand.
The BRCA test, which is related to both breast and ovarian cancer, will be provided to medium and large hospitals, government-affiliated medical institutions, health centers, and the general public through MP Group's new entrusted laboratories.
NGeneBio's BRCAaccuTest PLUS will be used to detect mutations in BRCA1/BRCA 2 genes and to analyze individuals' innate breast cancer, ovarian cancer risk, and family history to provide personalized reports.
“BRCAaccuTest PLUS is a medical device certified by Thai medical authorities and can be used as a diagnostic test for prescribing breast cancer-targeted treatments and for screening mutations in the BRCA1/BRCA 2 gene,” said Rittichai Srivijarn, chairman of MP Group.
"Thailand is the largest ASEAN country with the largest medical device market and is a stepping stone for us to ramp up
our presence in Southeast Asia, including countries like Singapore and Vietnam,” said NGeneBio's CEO Choi DaeChul.
Write to Jong Min Nam at
peux@hankyung.com
